Skip to main content Skip to footer
Algernon Pharmaceuticals Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Mar 06, 2020 6:09am EST

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Feb 26, 2020 6:00am EST

Algernon Pharmaceuticals to be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Feb 21, 2020 6:00am EST

Algernon Pharmaceuticals Announces Increase and Closing of CDN$1.55M Private Placement

Feb 13, 2020 9:00am EST

Algernon Pharmaceuticals Announces Private Placement

Feb 07, 2020 6:00am EST

Algernon Pharmaceuticals Appoints Professor of Respiratory Medicine Dr. Jacky Smith to Its Medical and Scientific Advisory Board

Jan 17, 2020 6:00am EST

Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment

Dec 30, 2019 6:00am EST

Algernon Pharmaceuticals Announces OTC Trading Symbol Change to AGNPF

Dec 16, 2019 6:00am EST

Algernon Pharmaceuticals Appoints Leading Respirologist Dr. Martin Kolb to Its Medical and Scientific Advisory Board

Dec 10, 2019 6:00am EST

Algernon Pharmaceuticals to Present at 12th Annual LD Micro Main Event Conference on Wednesday December 11, 2019

Dec 09, 2019 6:00am EST

Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap